Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4

Protagonist Therapeutics, Inc

2025-Q3 EPS reported -$1.35 revenue$38,579,000

Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.
Cash $678.8M, up from $559.2M at year-end 2024; provides runway through at least end 2028.
Icotrokinra NDA submitted to FDA (July) and EMA (September) for moderate-to-severe plaque psoriasis.
Rusfertide granted FDA Breakthrough Therapy designation; Phase 3 VERIFY 52-week data at ASH Dec 2025; NDA filing expected Q4 2025.
First patient dosed in Phase 1 for oral IL-17 antagonist PN-881.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.